Tip os
Log ind
Genmab_logo_silver_on_green.jpg

Partner exercises option on Genmab’s pipeline hope

Top picks in English:

Genmab’s US partner Seattle Genetics has accepted to co-develop of the Danish biotech company’s most promising candidate.


BY MARTIN HAVTORN PETERSEN AND RITZAU FINANS
Offentliggjort 30.08.17 kl. 15:55

Log ind for at læse artikler

Velkommen til MedWatch. En del af vores indhold er eksklusivt og forbeholdt vores brugere.

Prøv os gratis i 14 dage

Få fuld adgang til vores kvalitetsjournalistik med et gratis prøveabonnement.

Sign up for MedWatch newsletter
Mest læste Top picks in English

Widex goes along with rechargeability trend

widex headquarters.jpg Top picks in English:

Denmark’s third largest manufacturer of hearing aids, Widex, is getting on board with the latest trend in the business and launching a rechargeable solution for its top-line product Beyond.

MSD fined for employee’s LinkedIn post

Top picks in English:

Sharing product-related news on the social media LinkedIn had consequences for an employee in the Danish unit of MSD. The post could be regarded as advertisement and has resulted in a fine from The Ethical Committee for the Pharmaceutical Industry.

Leo Pharma announces new results for biologic hope

Top picks in English:

New phase III data from a study of one of Leo Pharma’s biologic drugs, Kyntheum, show significant benefits from long-term treatment with the drug.

Here is what Danish drug companies pay their workers

Top picks in English:

The average monthly salary in the private pharmaceutical industry in Denmark is DKK 57,109. Make the jump to find out which company pays the highest wages and learn how much the rest of the industry pays as well.

Veloxis hires chief scientific officer from BMS

Top picks in English:

The Danish biotech company Veloxis has hired a new chief science officer to manage the company's regulatory and medical affairs departments. The new CSO joins Veloxis from a position in US-based Bristol-Myers Squibb.

Analyst: William Demant gains ground on GN Resound

Top picks in English:

With the launch of a new wireless device, William Demant is catching up to rival and market leader in the 2.4 Ghz segment, GN Resound. But it is doubtful whether Demant’s new product can leave GN in the dust, says senior analyst Morten Imsgard from Sydbank.

Forsiden lige nu

Valutafald giver tæsk til medicinal- og medicoselskaber

markedet falder klar.jpg Medicinal & Biotek:

Sjældent har den danske krone stået stærkere over for en række af de største udenlandske valutaer, og det koster danske medicinal- og medicoproducenter dyrt. Den negative indflydelse på selskabernes regnskaber vil vare ved, vurderer analytiker.

Komité splittet i vurdering af Pfizers Sutent mod nyrekræft

Medicinal & Biotek:

En ekspertkomite under FDA har afleveret en uklar indstilling til lægemiddelmyndigheden, der skal vurdere, om Pfizers middel Sutent skal godkendes til behandling af patienter med høj risiko for tilbagefald.

Manglende udvalgsformænd til Medicinrådet ventes snart på plads

Medicinal & Biotek:

Dansk Selskab for Klinisk Onkologi forventer snart at kunne sætte navn på tre kandidater til ledige formandsposter i Medicinrådets fagudvalg.

Endnu en hedgefond satser på fald for Bavarian-aktien

Medicinal & Biotek:

Hedgefonden Citadel er gået 'short' i Bavarian Nordic-aktien, der fredag faldt med 48 pct.

Kreativ patentoverdragelse kan være en trussel mod innovation

Meninger:

Allergans 'indianer-finte' er potentielt farligt for innovationskraften og en foræring til dem, der mener, at medicinalbranchen alt for ofte overskrider etiske grænser, skriver Marianne Johansen i denne klumme.

Bayer dropper omstridt "p-pille"-implantat i Europa

Medicinal & Biotek:

Tyske Bayer har nu valgt at droppe salget af dets omstridte svangerskabsforebyggende implantat Essure i Europa. Beslutningen er udelukkende taget af kommercielle årsager og er ikke forbundet med sikkerhed eller kvalitet, lyder det fra selskabet.

ANNONCE
ANNONCE


ANNONCE